Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin ER plus immune checkpoint inhibitor maintenance for advanced lung squamous cell carcinoma
ChiCTR2500107128Phase 4Not yet recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Pulmonary squamous cell carcinoma comparing Immune checkpoint inhibitor + metformin ER maintenance with Immune checkpoint inhibitor + placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2500107128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107128.